2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Colorectal Neoplasms
128
Colonic Neoplasms
54
Rectal Neoplasms
49
Carcinoma, Hepatocellular
29
Stomach Neoplasms
23
Neoplasm Metastasis
22
Neoplasms
11
Pancreatic Neoplasms
10
Cholangiocarcinoma
9
Adenocarcinoma Of Esophagus
8
Esophageal Neoplasms
7
Liver Neoplasms
6
Gastrointestinal Neoplasms
5
Biliary Tract Neoplasms
5
Recurrence
4
Ovarian Neoplasms
4
Esophageal Squamous Cell Carcinoma
3
Digestive System Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Adenocarcinoma
3
Unresectable Metastatic Colorectal Cancer
2
Peritoneal Neoplasms
2
Neurotoxicity Syndromes
2
Neoplastic Cells, Circulating
2
Intestinal Neoplasms
2
Gastrointestinal Diseases
2
Gallbladder Neoplasms
2
Colorectal Cancer Metastatic
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Interventions
Sunitinib
145
Nivolumab
144
pembrolizumab
132
Sorafenib
84
Bevacizumab
77
Everolimus
74
cabozantinib
71
pazopanib
65
Axitinib
65
Ipilimumab
62
aldesleukin
52
Magnetic Resonance Spectroscopy
45
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
37
Specimen Handling
36
Radiosurgery
36
Interferon-alpha
32
atezolizumab
30
temsirolimus
27
belzutifan
24
Gemcitabine
23
fludarabine phosphate
22
avelumab
22
Radiotherapy
19
Interferon alpha-2
19
Biopsy
18
fludarabine
17
durvalumab
17
Nephrectomy
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Folfox protocol
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled